Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR1 | Q8TCW9 | 4/20 | 0.42 |
| ▸ | MGLL | Q99685 | 6/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27166109 | 0.88 | PROKR1 (0.44) | PROKR1MGLLMAPTKMT2AMEN1 | |
| SCHEMBL30056286 | 0.88 | MGLL (0.40) | MGLLKMT2AMEN1 | |
| SCHEMBL27166097 | 0.88 | MGLL (0.40) | MGLLKMT2AMEN1 | |
| SCHEMBL29205161 | 0.83 | PROKR1 (0.42) | PROKR1MGLLMAPT | |
| SCHEMBL27166033 | 0.83 | PROKR1 (0.44) | PROKR1MGLLMAPTKMT2AMEN1 | |
| SCHEMBL27166130 | 0.81 | PROKR1 (0.45) | PROKR1MGLLMAPT | |
| SCHEMBL27166031 | 0.80 | ALOX5 (0.48) | PROKR1MGLLFAAHMAPTKMT2A | |
| SCHEMBL29205166 | 0.79 | ALDH1A1 (0.52) | PROKR1KMT2AAKR1C3 | |
| SCHEMBL27166104 | 0.79 | ALDH1A1 (0.50) | PROKR1MAPTKMT2AMEN1AKR1C3 | |
| SCHEMBL27166193 | 0.78 | PROKR1 (0.43) | PROKR1MGLLMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637471-B2 | Heterocyclic compounds, compositions, methods of preparation and uses thereof | ORGANON R&D FINLAND LTD. (FI) | 2026-05-26 | — | — | US | disclosed |
| EP-4334289-B1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | Organon R&D Finland Oy (FI) | 2025-06-25 | — | — | EP | disclosed |
| US-20240254131-A1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | ORGANON R&D FINLAND LTD. (FI) | 2024-08-01 | — | — | US | disclosed |
| CN-117794899-A | Novel heterocyclic compounds, compositions, methods of preparation and uses thereof | 欧加农研发芬兰有限公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4334289-A1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | Organon R&D Finland Ltd (FI) | 2024-03-13 | — | — | EP | disclosed |
| WO-2022234193-A1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | FORENDO PHARMA LTD (FI) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254131-A1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | AKR1C3, AKR1C4, AKR1C1 | PROKR1 1639/4885MGLL 1354/4885FAAH 416/4885 |
| US-12637471-B2 | Heterocyclic compounds, compositions, methods of preparation and uses thereof | AKR1C3, AKR1C4, AKR1C2 | PROKR1 1682/4885MGLL 450/4885FAAH 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.